Davis 1982.

Methods	Design: Double‐blind randomized placebo controlled crossover study Two to 4 days generally separated each infusion (occurred at the same time of day)
Participants	Country: USA Number: 10 patients Sex: 8 males; 2 females Age: 50‐68 years Severity of AD: moderate Patients with at least 1‐year history of progressive memory loss Diagnosis criteria: Clinical history, physical examination, CAT scan, brain skull films, CSF analysis and serum analysis (for excluding other conditions). Not clear if all patients had such radiologic and laboratory examinations. MIT < =10 DRS > =4
Interventions	1. placebo 2. physostigmine i.v.optimal dose ( 0.125, 0.25 or 0.5mg dissolved in 100cc of normal saline at a constant rate over 30 min.)+2.5mg Probanthine, a cholinergic antagonist that does not cross the blood‐brain barrier, i.v. 5 min before every infusion to minimize physostigmine's peripheral effects.
Outcomes	Famous faces test (retrieval from remote memory) Digit span test Word or picture recognition test (recognition memory test)
Notes	Optimal dose found in a prior dose finding phase. All patients were free of psychoactive medications for at least two weeks prior to physostigmine. Results were subjected to a technique (signal detectability analysis) which suggested that new items were more discriminable following physostigmine, and that patient's criteria for saying that they recognized an item also changed with physostigmine infusion.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear